Global Information
회사소개 | 문의 | 비교리스트

탄저병(감염증) : 개발중인 약제(2021년)

Anthrax (Infectious Disease) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 03월 상품코드 1000854
페이지 정보 영문 124 Pages 배송안내
가격
US $ 2,000 ₩ 2,841,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 5,682,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 8,523,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


탄저병(감염증) : 개발중인 약제(2021년) Anthrax (Infectious Disease) - Drugs in Development, 2021
발행일 : 2021년 03월 페이지 정보 : 영문 124 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

탄저병은 탄저균에 의해 발생되는 심각한 감염증입니다. 주요 징후·증상으로 구역, 구토, 복통, 두통, 식욕 부진, 발열, (질환 후기 단계에서의) 중증 혈리, 인후통, 연하곤란 등이 포함되어 있습니다. 위험 요인에는 불법 약물의 주사, 동물 피부의 취급, 수의학 관련 업무(특히 가축의 취급) 등이 포함되어 있습니다.

세계 각국에서 탄저병 치료용 파이프라인 제품의 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향 및 임상시험의 각 단계에 있는 제품의 리스트, 주요 기업의 개요, 주요 약제의 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

목차

  • 서론
  • 탄저병 : 개요
  • 탄저병 : 치료제 개발
  • 탄저병 : 치료제 평가
  • 탄저병 : 치료제 개발에 참여하고 있는 기업
  • 탄저병 : 약제 개요
  • 탄저병 : 개발이 휴지 상태인 제품
  • 탄저병 : 개발이 중지된 제품
  • 탄저병 : 제품 개발 마일스톤
  • 부록
KSA 21.05.20

List of Tables

  • Number of Products under Development for Anthrax, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Anthrax - Pipeline by Altimmune Inc, 2021
  • Anthrax - Pipeline by Aphios Corp, 2021
  • Anthrax - Pipeline by Aradigm Corp (Inactive), 2021
  • Anthrax - Pipeline by Biologics Resources LLC, 2021
  • Anthrax - Pipeline by BlueWillow Biologics Inc, 2021
  • Anthrax - Pipeline by China Biologic Products Holdings Inc, 2021
  • Anthrax - Pipeline by Crestone Inc, 2021
  • Anthrax - Pipeline by Dynavax Technologies Corp, 2021
  • Anthrax - Pipeline by Emergent BioSolutions Inc, 2021
  • Anthrax - Pipeline by GC Pharma, 2021
  • Anthrax - Pipeline by Greffex Inc, 2021
  • Anthrax - Pipeline by Hawaii Biotech Inc, 2021
  • Anthrax - Pipeline by iBio Inc, 2021
  • Anthrax - Pipeline by Innovative Biologics Inc, 2021
  • Anthrax - Pipeline by Integrated BioTherapeutics Inc, 2021
  • Anthrax - Pipeline by iNtRON Biotechnology Inc, 2021
  • Anthrax - Pipeline by Opal Biosciences Ltd, 2021
  • Anthrax - Pipeline by Paratek Pharmaceuticals Inc, 2021
  • Anthrax - Pipeline by Protein Potential LLC, 2021
  • Anthrax - Pipeline by ProThera Biologics Inc, 2021
  • Anthrax - Pipeline by Soligenix Inc, 2021
  • Anthrax - Pipeline by Vast Therapeutics Inc, 2021
  • Anthrax - Pipeline by Venomyx Inc, 2021
  • Anthrax - Pipeline by VLP Biotech Inc, 2021
  • Anthrax - Dormant Projects, 2021
  • Anthrax - Dormant Projects, 2021 (Contd..1)
  • Anthrax - Dormant Projects, 2021 (Contd..2)
  • Anthrax - Dormant Projects, 2021 (Contd..3)
  • Anthrax - Discontinued Products, 2021

List of Figures

  • Number of Products under Development for Anthrax, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Drugs in Development, 2021, provides an overview of the Anthrax (Infectious Disease) pipeline landscape.

Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anthrax - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 17 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.

Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Anthrax - Overview
  • Anthrax - Therapeutics Development
  • Anthrax - Therapeutics Assessment
  • Anthrax - Companies Involved in Therapeutics Development
  • Anthrax - Drug Profiles
  • Anthrax - Dormant Projects
  • Anthrax - Discontinued Products
  • Anthrax - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q